Stereotaxis (STXS): Price and Financial Metrics


Stereotaxis (STXS): $5.87

-0.02 (-0.34%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

STXS POWR Grades


  • STXS scores best on the Quality dimension, with a Quality rank ahead of 72.66% of US stocks.
  • The strongest trend for STXS is in Stability, which has been heading down over the past 52 weeks.
  • STXS's current lowest rank is in the Growth metric (where it is better than 6.58% of US stocks).

STXS Stock Summary

  • The ratio of debt to operating expenses for Stereotaxis Inc is higher than it is for about only 19.6% of US stocks.
  • With a price/sales ratio of 13.07, Stereotaxis Inc has a higher such ratio than 86.45% of stocks in our set.
  • With a year-over-year growth in debt of 32.01%, Stereotaxis Inc's debt growth rate surpasses 81.21% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Stereotaxis Inc, a group of peers worth examining would be SUMO, DMRC, ZUO, BFLY, and VRNS.
  • STXS's SEC filings can be seen here. And to visit Stereotaxis Inc's official web site, go to www.stereotaxis.com.

STXS Valuation Summary

  • STXS's price/sales ratio is 15.8; this is 39.21% higher than that of the median Healthcare stock.
  • STXS's EV/EBIT ratio has moved down 83.7 over the prior 208 months.
  • Over the past 208 months, STXS's price/sales ratio has gone down 2.8.

Below are key valuation metrics over time for STXS.

Stock Date P/S P/B P/E EV/EBIT
STXS 2021-08-31 15.8 14.4 -76.8 -89.3
STXS 2021-08-30 14.2 13.0 -69.0 -79.4
STXS 2021-08-27 14.0 12.7 -67.7 -77.8
STXS 2021-08-26 14.0 12.7 -67.9 -78.1
STXS 2021-08-25 14.1 12.9 -68.5 -78.9
STXS 2021-08-24 14.7 13.4 -71.4 -82.5

STXS Growth Metrics

  • Its year over year revenue growth rate is now at 6.68%.
  • Its 4 year net income to common stockholders growth rate is now at 9.73%.
  • Its 5 year price growth rate is now at 291%.
STXS's revenue has moved down $4,069,336 over the prior 70 months.

The table below shows STXS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 33.60519 -0.582029 -9.889141
2021-06-30 33.20232 -0.445619 -6.847937
2021-03-31 29.49635 -1.651173 -7.565574
2020-12-31 26.63003 -3.511772 -8.01588
2020-09-30 26.6981 -5.734686 -7.937102
2020-06-30 26.19626 -5.657559 -6.337928

STXS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • STXS has a Quality Grade of B, ranking ahead of 89.02% of graded US stocks.
  • STXS's asset turnover comes in at 0.581 -- ranking 75th of 186 Medical Equipment stocks.
  • FONR, SMLR, and KIDS are the stocks whose asset turnover ratios are most correlated with STXS.

The table below shows STXS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.581 0.676 -2.014
2021-03-31 0.516 0.684 -1.715
2020-12-31 0.504 0.712 -1.512
2020-09-30 0.536 0.708 -1.279
2020-06-30 0.565 0.786 -0.976
2020-03-31 0.739 0.795 -0.864

STXS Stock Price Chart Interactive Chart >

Price chart for STXS

STXS Price/Volume Stats

Current price $5.87 52-week high $10.30
Prev. close $5.89 52-week low $4.20
Day low $5.67 Volume 453,500
Day high $6.03 Avg. volume 377,038
50-day MA $5.91 Dividend yield N/A
200-day MA $7.20 Market Cap 437.79M

Stereotaxis (STXS) Company Bio


Stereotaxis Inc. designs, manufactures, and markets advanced cardiology instrument control system for use in the cath lab that is used in the treatment of coronary artery disease and arrhythmias. The Company markets Stereotaxis System in the United States and Europe.


STXS Latest News Stream


Event/Time News Detail
Loading, please wait...

STXS Latest Social Stream


Loading social stream, please wait...

View Full STXS Social Stream

Latest STXS News From Around the Web

Below are the latest news stories about Stereotaxis Inc that investors may wish to consider to help them evaluate STXS as an investment opportunity.

Stereotaxis to Host Inaugural Innovation Day Pioneering Endovascular Robotics

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentations of the companys innovation pipeline by members of Stereotaxis leadership with a live Q&A session.

Wallstreet:Online | November 18, 2021

Stereotaxis to Host Inaugural Innovation Day – Pioneering Endovascular Robotics

ST. LOUIS, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it will host an inaugural Innovation Day by live webcast on December 13. The event will include presentations of the company’s innovation pipeline by members of Stereotaxis leadership with a live Q&A session. What: Stereotaxis Innovation Day – Pioneering Endovascular RoboticsWhen: Monday, December 13, 2021 at 4:0

Yahoo | November 18, 2021

BJC HealthCare Becomes First Health Care System in Midwest to Adopt Latest Robotic Technology for Arrhythmia Treatment

ST. LOUIS, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE:STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, announces today that BJC HealthCare has become the first health care system in the midwest to offer the Genesis RMN system, advancing electrophysiology patient care and expanding access to advanced robotic technology for the treatment of cardiac arrhythmias in the greater St. Louis region.

Intrado Digital Media | November 15, 2021

Stereotaxis (NYSEAMERICAN:STXS) Issues Earnings Results, Misses Estimates By $0.03 EPS

Stereotaxis (NYSEAMERICAN:STXS) posted its quarterly earnings data on Thursday. The company reported ($0.07) EPS for the quarter, missing analysts consensus estimates of ($0.04) by ($0.03), MarketWatch Earnings reports. Stereotaxis had a negative return on equity of 24.21% and a negative net margin of 25.42%. Shares of STXS stock opened at $6.52 on Friday. Stereotaxis has []

Transcript Daily | November 14, 2021

Stereotaxis EPS misses by $0.03, beats on revenue

Stereotaxis (NYSE:STXS): Q3 GAAP EPS of -$0.07 misses by $0.03. Revenue of $9.1M (+4.6% Y/Y) beats by $0.07M. Press Release...

Seeking Alpha | November 11, 2021

Read More 'STXS' Stories Here

STXS Price Returns

1-mo -3.45%
3-mo -14.80%
6-mo -24.74%
1-year 30.73%
3-year 313.38%
5-year 967.27%
YTD 15.32%
2020 -3.78%
2019 389.36%
2018 35.13%
2017 23.10%
2016 -12.18%

Continue Researching STXS

Want to see what other sources are saying about Stereotaxis Inc's financials and stock price? Try the links below:

Stereotaxis Inc (STXS) Stock Price | Nasdaq
Stereotaxis Inc (STXS) Stock Quote, History and News - Yahoo Finance
Stereotaxis Inc (STXS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.731 seconds.